Customize your JAMA Network experience by selecting one or more topics from the list below.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Kimbrough CW, Beal E, Abdel-Misih S, Pawlik TM, Cloyd JM. Survival Outcomes Among Patients With Gastric Adenocarcinoma Who Received Hyperthermic Intraperitoneal Chemotherapy With Cytoreductive Surgery. JAMA Surg. 2019;154(8):780–782. doi:10.1001/jamasurg.2019.1698
Gastric cancer (GC) with peritoneal metastases is associated with a poor prognosis. Median overall survival (OS) is less than 1 year with systemic chemotherapy alone.1 Hyperthermic intraperitoneal chemotherapy (HIPEC) combined with cytoreductive surgery (CRS) has been used for various peritoneal surface malignant tumors, and there has been marked interest in its application to GC because a small randomized clinical trial demonstrated improved OS among patients who underwent CRS-HIPEC compared with CRS alone.2 Although widespread adoption of HIPEC for GC has been limited because of poor oncologic outcomes and high perioperative morbidity,3 interest in the use of intraperitoneal chemotherapy for patients with advanced GC persists.1 We assessed survial outcomes among patients with gastric adenocarcinoma who received CRS-HIPEC at academic centers across the United States.
Create a personal account or sign in to: